ArticleCureus2026
Definitive Radiotherapy for Unresectable Unicentric Mediastinal Castleman Disease: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease is a rare nonclonal lymphoproliferative disorder with heterogeneous clinical presentations and therapeutic approaches. Surgery remains the standard treatment for unicentric Castleman disease, while radiotherapy may represent an alternative option in unresectable cases. We report the case of a 17-year-old female who presented with exertional dyspnea related to a right hilar mediastinal mass. Chest computed tomography revealed a well-circumscribed lesion closely related to adjacent vascular and bronchial structures. Histopathological examination demonstrated abnormal lymphoid follicles with atrophic germinal centers producing the characteristic "onion-skin" appearance. Immunohistochemical analysis showed a CD3-, CD20+, CD21+, Bcl2-, and CD5- profile consistent with the hyaline vascular subtype of unicentric Castleman disease. Positron emission tomography/computed tomography demonstrated localized hypermetabolic mediastinal lymphadenopathy without distant involvement. Due to close vascular relationships and high hemorrhagic risk, the lesion was considered unresectable after multidisciplinary discussion. The patient underwent definitive volumetric modulated arc therapy (VMAT) delivering 39.6 Gy in 22 fractions. Treatment was well tolerated without significant acute or late toxicity. After 13 months of follow-up, clinical and radiological evaluation demonstrated a favorable response, with approximately 50% tumor reduction according to RECIST v1.1 criteria, improvement in dyspnea from New York Heart Association (NYHA) class III to class II, and normalization of pulmonary function tests. This case highlights the potential role of definitive radiotherapy as an effective and well-tolerated therapeutic alternative in unresectable unicentric mediastinal Castleman disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.